Arcutis Biotherapeutics

Arcutis Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company headquartered in Westlake Village, California, specializing in the development and commercialization of treatments for immune-mediated dermatological diseases. Founded in 2016, Arcutis is focused on addressing unmet medical needs in dermatology by leveraging advances in immunology and inflammation. Its lead product candidate, a topical cream formulation of roflumilast, is undergoing Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. Additionally, the company is developing other innovative therapies, including a topical foam formulation for seborrheic dermatitis and scalp psoriasis, a selective small molecule inhibitor for hand eczema, and a specialized formulation designed for alopecia areata. Arcutis aims to provide differentiated therapies that effectively tackle persistent treatment challenges in serious skin conditions.

David Topper

CFO, Finance

1 past transactions

Ducentis BioTherapeutics

Acquisition in 2022
Ducentis BioTherapeutics Limited is a pre-clinical stage company based in Witney, United Kingdom, focused on developing novel therapies for inflammation and autoimmune diseases. Established in 2014, the company aims to modify a naturally occurring protein with significant immunoregulatory functions. Ducentis targets the CD200/CD200R axis, which delivers a deactivating signal to activated immune cells in both the innate and adaptive immune systems. Their potential therapeutic applications include addressing transplant rejection and treating various autoimmune and inflammatory diseases that affect the lungs, liver, kidneys, eyes, bones, and cartilage.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.